Updated September 4 at 2:04pm

Enter your email to receive Providence Business News' e-newsletters
and breaking news alerts.  


Without tax benefit, Alexion profit drops in 4Q to $26.5M from $237.1M


SMITHFIELD - Alexion Pharmaceuticals Inc., the Cheshire, Conn.-based manufacturer of Soliris, a drug used to treat a rare, life-threatening blood disorder, released its fourth-quarter and full-year results Thursday.

Net income for Alexion totaled $97.03 million, or $1.04 per diluted share, compared with 2009 totals of $295.17 million, or $3.26 per share. The company’s previous year results had been helped by a $215.5 million non-recurring tax benefit.

For the full year, product sales were $540.96 million, up from $386.8 million a year earlier.

Fourth-quarter 2010 profit fell to $26.45 million, or 28 cents per diluted share, from $237.13 million, or $2.59 per share, as seen in the fourth quarter of 2009, which is when the company took that $215.5 million tax benefit.

Product sales increased to $155.98 million for the three months ended Dec. 31 from $110.65 million.

In January and February 2011, Alexion used $114 million of available cash for acquisitions. The company announced an upfront cash payment of $3 million – plus contingent payments based on various development, regulatory and commercial milestones - for the purchase of patents and assets from Germany-based Orphatec Pharmaceuticals GmbH related to an investigational therapy for patients with molybdenum cofactor deficiency Type A.

On Jan. 31, Alexion acquired Taligen Therapeutics Inc., a privately-held development-stage biotechnology company based in Cambridge, Mass., for an upfront cash payment of $111 million.

In announcing the results, Alexion highlighted the market performance of Soliris, which is the only drug specifically indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria, a rare, debilitating and life-threatening blood disease.

Alexion Pharmaceuticals, Alexion, Soliris, Cheshire, Connecticut, Orphatec, Pharmaceuticals, GMBH, investigation, biotechnology, Cambridge, Massachusetts, hemog fourth quarter, profit, fell, share, 2009, GAAP, sales, earnings, results,


No comments on this story | Please log in to comment by clicking here
Please log in or register to add your comment
Latest News